Undiscovered Gems in India to Watch This September 2024
In This Article:
The Indian market has climbed 1.0% over the last week and is up 45% over the last 12 months, with earnings expected to grow by 17% per annum over the next few years. In this favorable environment, identifying stocks with strong growth potential and solid fundamentals can offer promising opportunities for investors.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Bengal & Assam | 4.48% | 1.53% | 51.11% | ★★★★★★ |
| Bharat Rasayan | 8.15% | 0.10% | -7.93% | ★★★★★★ |
| Pearl Global Industries | 72.24% | 19.89% | 41.91% | ★★★★★☆ |
| Network People Services Technologies | 0.24% | 81.82% | 86.36% | ★★★★★☆ |
| Macpower CNC Machines | 0.40% | 22.04% | 31.09% | ★★★★★☆ |
| BLS E-Services | 1.67% | 15.04% | 51.58% | ★★★★★☆ |
| Share India Securities | 24.23% | 37.66% | 48.98% | ★★★★☆☆ |
| Sanstar | 50.30% | -8.41% | 48.59% | ★★★★☆☆ |
| Vasa Denticity | 0.11% | 38.37% | 48.77% | ★★★★☆☆ |
| Abans Holdings | 91.77% | 13.13% | 18.72% | ★★★★☆☆ |
Here we highlight a subset of our preferred stocks from the screener.
Netweb Technologies India
Simply Wall St Value Rating: ★★★★★★
Overview: Netweb Technologies India Limited designs, manufactures, and sells high-end computing solutions (HCS) in India with a market cap of ?153.40 billion.
Operations: Netweb Technologies India Limited generates revenue primarily from the manufacturing and sale of computer servers, amounting to ?8.14 billion.
Netweb Technologies India has demonstrated impressive growth, with earnings increasing by 85.8% over the past year, significantly outpacing the tech industry's 10.8%. The company's debt to equity ratio has improved dramatically from 108% to just 2.3% in five years, indicating robust financial health. Recent Q1 results show net income rising to INR 154 million from INR 51 million a year ago, reflecting strong operational performance and high-quality earnings.
Orchid Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Orchid Pharma Limited is a pharmaceutical company involved in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India with a market cap of ?77.14 billion.
Operations: Orchid Pharma Limited generates revenue primarily from its pharmaceuticals segment, amounting to ?8.81 billion.
Orchid Pharma has shown impressive earnings growth of 44.6% over the past year, outperforming the broader pharmaceuticals industry at 19.3%. The company’s net debt to equity ratio stands at a satisfactory 11.3%, indicating strong financial health. Recent regulatory issues have surfaced with a GST audit revealing liabilities totaling INR 49.95 million for FY2019-2020, but this hasn't hindered their performance as Q1 sales for FY2024 reached INR 2,444 million compared to INR 1,829 million last year.